Jm. Pell et al., Enhancement of insulin-like growth factor I activity by novel antisera: Potential structure/function interactions, ENDOCRINOL, 141(2), 2000, pp. 741-751
Insulin-like growth factor I(IGF-I) is essential for normal growth and deve
lopment, regulating cell proliferation, differentiation, and survival. Litt
le IGF-I exists in the free form; rather, it is bound to one of a family of
six specific IGF-binding proteins (IGFBPs). Usually, IGFBPs have a high af
finity for IGF-I and inhibit its activity. Intriguingly, some IGFBPs also p
otentiate IGF-I action; the precise mechanism of this is unclear, but it is
thought to include modification of the IGFBP to lower its affinity for IGF
-I. We have previously generated a novel antihuman (h) IGF-I antiserum that
, instead of inhibiting IGF-I activity, enhances it in vivo. As the enhanci
ng anti-IGF-I antiserum and potentiating IGFBPs share several properties wi
th regard to IGF action, the antibody may provide a model for examining the
actions of enhancing IGFBPs. In this study we demonstrate that the antiser
um can also enhance IGF-I activity in vitro, assessed as cell number of a b
ovine fibroblast cell line, suggesting that its actions might not merely be
confined to changing the kinetics of IGF-I clearance or degradation. Epito
pe scanning using overlapping octamer and hexamer peptides spanning the ent
ire sequence of IGF-I indicates that the enhancing antiserum recognizes a s
pecific linear region spanning the C-terminal region of the C domain and th
e proximal A domain (residues Ser(33) to Cys(47)), and that this recognitio
n is not present in nonenhancing antisera. Further, this region is located
on the opposite surface of IGF-I from putative type 1 receptor-binding resi
dues, allowing the possibility that the antiserum might be able to modulate
IGF-I receptor binding. Antibodies raised against a synthetic peptide corr
esponding to Ser33 to Cys47 Of IGF-I also potentiated IGF-I activity in viv
o. its TGF-I may be beneficial in various clinical conditions associated wi
th catabolism or cell repair, we suggest that this potentiating anti-IGF-I
antiserum has favorable properties that could form a basis for therapeutic
strategy.